» Articles » PMID: 29972824

Haemodialysis with Tinzaparin Versus Dialysate Citrate As Anticoagulation

Overview
Journal Blood Purif
Specialty Hematology
Date 2018 Jul 5
PMID 29972824
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Anticoagulation with citrate-containing haemodialysate (cHD) is an alternative to tinzaparin haemodialysate (tHD). The study investigated whether cHD would differ when changed from tHD. The same 18 patients were their own controls followed up with cHD for 5 months. LDL-cholesterol decreased at the end of a cHD session (p = 0.01). Neutrophils (p = 0.013) and monocytes (p = 0.007) dropped more during a cHD session. During the follow-up period of cHD, approximately 50% needed additional tinzaparin. Before the cHD session could start, there was a lower total cholesterol at 2 weeks (p = 0.014) and LDL-cholesterol at 1 month (p = 0.011) versus an increase of LDL at 5 months (p = 0.02). Only patients without additional tinzaparin had a reduction of -C-reactive protein (CRP) at 2 months of cHD (p < 0.05) but not later. Solely cHD seems possible only in half of the patients. A greater reduction in granulocytes and monocytes during cHD indicates a more extensive blood membrane interaction, while CRP may be lower.

Citing Articles

Double Pump Sequential Constant Citrate Anticoagulation in General Hemodialysis.

Tang L, Zhang J, Cheng Q, Li J, Zhou L, Wang L Appl Bionics Biomech. 2022; 2022:6047074.

PMID: 35928576 PMC: 9345715. DOI: 10.1155/2022/6047074.


Modified regional citrate anticoagulation is optimal for hemodialysis in patients at high risk of bleeding: a prospective randomized study of three anticoagulation strategies.

Lin T, Song L, Huang R, Huang Y, Tang S, Lin Q BMC Nephrol. 2019; 20(1):472.

PMID: 31856749 PMC: 6924029. DOI: 10.1186/s12882-019-1661-y.